Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity

Complement-dependent cytotoxicity (CDC) is thought to be one of the most important mechanisms of action of therapeutic monoclonal antibodies (mAbs). The decay-accelerating factor (DAF) overexpressed in certain tumors limits the CDC effect of the therapeutic anticancer antibodies. The use of DAF bloc...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical immunology (Orlando, Fla.). - 1999. - 128(2008), 2 vom: 01. Aug., Seite 155-63
1. Verfasser:	Guo, Bo (VerfasserIn)
Weitere Verfasser:	Ma, Zheng-wei, Li, Hua, Xu, Gui-lian, Zheng, Ping, Zhu, Bo, Wu, Yu-Zhang, Zou, Qiang
Format:	Online-Aufsatz
Sprache:	English
Veröffentlicht:	2008
Zugriff auf das übergeordnete Werk:	Clinical immunology (Orlando, Fla.)
Schlagworte:	Journal Article Research Support, Non-U.S. Gov't Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Antigens, CD20 Antineoplastic Agents CD55 Antigens Epitopes Rituximab 4F4X42SYQ6 mehr... Complement System Proteins 9007-36-7